Peroxisome proliferator-activated receptor-δ attenuates colon carcinogenesis

被引：185

作者：

Harman, FS

Nicol, CJ

Marin, HE

Ward, JM

Gonzalez, FJ

Peters, JM ^{[1
]}

机构：

[1] Penn State Univ, Dept Vet Sci, University Pk, PA 16802 USA

[2] Penn State Univ, Ctr Mol Toxicol & Carcinogenesis, University Pk, PA 16802 USA

[3] Penn State Univ, Grad Program Biochem Microbiol & Mol Biol, University Pk, PA 16802 USA

[4] NCI, Lab Metab, Bethesda, MD 20892 USA

[5] NCI, Vet & Tumor Pathol Sect, Off Lab Anim Resources, Frederick, MD 21702 USA

来源：

NATURE MEDICINE | 2004年 / 10卷 / 05期

关键词：

D O I：

10.1038/nm1026

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Peroxisome proliferator-activated receptor-delta (PPAR-delta; also known as PPAR-beta) is expressed at high levels in colon tumors, but its contribution to colon cancer is unclear. We examined the role of PPAR-delta in colon carcinogenesis using PPAR-delta-deficient (Ppard(-/-)) mice. In both the Min mutant and chemically induced mouse models, colon polyp formation was significantly greater in mice nullizygous for PPAR-delta. In contrast to previous reports suggesting that activation of PPAR-delta potentiates colon polyp formation, here we show that PPAR-delta attenuates colon carcinogenesis.

引用

页码：481 / 483

页数：3

共 15 条

[1] Effects of peroxisome proliferator-activated receptor δ on placentation, adiposity, and colorectal cancer
Barak, Y
Liao, D
He, WM
Ong, ES
Nelson, MC
Olefsky, JM
Boland, R
Evans, RM
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (01) : 303 - 308
[2] Use of the peroxisome proliferator-activated receptor (PPAR) γ ligand troglitazone as treatment for refractory breast cancer:: a phase II study
Burstein, HJ
Demetri, GD
Mueller, E
Sarraf, P
Spiegelman, BM
Winer, EP
[J]. BREAST CANCER RESEARCH AND TREATMENT, 2003, 79 (03) : 391 - 397
[3] APIC-dependent suppression of colon carcinogenesis by PPARγ
Girnun, GD
Smith, WM
Drori, S
Sarraf, P
Mueller, E
Eng, C
Nambiar, P
Rosenberg, DW
Bronson, RT
Edelmann, W
Kucherlapati, R
Gonzalez, FJ
Spiegelman, BM
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (21) : 13771 - 13776
[4] Prostacyclin-mediated activation of peroxisome proliferator-activated receptor δ in colorectal cancer
Gupta, RA
Tan, J
Krause, WF
Geraci, MW
Willson, TM
Dey, SK
DuBois, RN
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (24) : 13275 - 13280
[5] Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-δ accelerates intestinal adenoma growth
Gupta, RA
Wang, DZ
Katkuri, S
Wang, HB
Dey, SK
DuBois, RN
[J]. NATURE MEDICINE, 2004, 10 (03) : 245 - 247
[6] PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs
He, TC
Chan, TA
Vogelstein, B
Kinzler, KW
[J]. CELL, 1999, 99 (03) : 335 - 345
[7] A phase II study of troglitazone, an activator of the PPARγ receptor, in patients with chemotherapy-resistant metastatic colorectal cancer
Kulke, MH
Demetri, GD
Sharpless, NE
Ryan, DP
Shivdasani, R
Clark, JS
Speigelman, BM
Kim, H
Mayer, RJ
Fuchs, CS
[J]. CANCER JOURNAL, 2002, 8 (05) : 395 - 399
[8] Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APCMin/+ mice
Lefebvre, AM
Chen, IH
Desreumaux, P
Najib, J
Fruchart, JC
Geboes, K
Briggs, M
Heyman, R
Auwerx, J
[J]. NATURE MEDICINE, 1998, 4 (09) : 1053 - 1057
[9] Peroxisome-proliferator-activated receptors and cancers: Complex stories
Michalik, L
Desvergne, B
Wahli, W
[J]. NATURE REVIEWS CANCER, 2004, 4 (01) : 61 - 70
[10] Niho N, 2003, CANCER RES, V63, P6090

← 1 2 →